REFERENCES

1. Alkeridy WA, Almahplouth I, Alrasheed R, et al. A unique presentation of delirium in a patient with otherwise asymptomatic COVID-19. J Am Geriatr Soc. 2020;10.1111.jgs.16536.

2. Zhou L, Zhang M, Gao J, Wang J. Sars-Cov-2: underestimated damage to nervous system. Travel Med Infect Dis. 2020;101642. https://doi.org/10.1016/j.trmed.2020.101642.

3. Susswein AJ, Katzoff A, Miller N, Hurwitz I. Nitric oxide and memory. Neuroscientist. 2004;10:153-162.

4. Garthwaite J, Boulton CL. Nitric oxide signaling in the nervous system. Annu Rev Physiol. 1995;57:683-706.

5. Paul V, Ekambaram P. Involvement of nitric oxide in learning & memory processes. Indian J Med Res. 2011;133:471-478.

6. Tseng K, Caballero A, Dec A, et al. Inhibition of striatal soluble guanylate cyclase-cGMP signaling reverses basal ganglia dysfunction and akinesia in experimental parkinsonism. PLoS One. 2011;6:e27187.

7. Cao Z, Wu Y, Faucon E, Sabatier JM. SARS-CoV-2 & Covid-19: key-roles of the ‘renin-angiotensin’ system/vitamin D impacting drug and vaccine developments. Infect Disord Drug Targets. 2020;20:1.

8. Doobay MF, Talman LS, Obr TD, Tian X, Davison RL, Lazarigue E. Differential expression of neuronal ACE2 in transgenic mice with over-expression of the brain renin-angiotensin system. Am J Physiol Regul Integr Comp Physiol. 2007;292:R373-R381.

9. Dasgupta C, Zhang L. Angiotensin B receptors and drug discovery in cardiovascular disease. Drug Discov Today. 2011;16:22-34.

10. Annweiler C, Cao Z, Wu Y, et al. Counter-regulatory ‘Renin-Angiotensin’ System-based candidate drugs to treat COVID-19 diseases in SARS-CoV-2-infected patients. Infect Disord Drug Targets. 2020. https://doi.org/10.2174/1871526520666200518073329.

Acknowledgments

Conflict of Interest: The authors have declared no conflicts of interest for this letter to the editor.

Author Contributions: Study concept and design: All authors. Analysis and interpretation of data: All authors. Drafting of the manuscript: Annweiler and Sabatier. Critical revision of the manuscript for important intellectual content: Bourgeais, Faucon, Cao, and Wu. Administrative, technical, or material support: Annweiler. Study supervision: Annweiler and Sabatier.

Sponsor’s Role: None.

Reply to: Neurological, Cognitive and Behavioral Disorders During COVID-19: The Nitric Oxide Track

To the Editor: We read with great interest the letter of Annweiler et al.1 They propose an intriguing mechanism for cognitive impairment related to coronavirus disease 2019 (COVID-19). We would like to clarify a couple of points related to our case. First, although we wanted to exclude COVID-19 encephalitis as a possibility, this was not possible without cerebrospinal fluid analysis and magnetic resonance imaging, which was refused by our patient. Our patient fulfilled the Confusion Assessment Method criteria for delirium on admission, which was our working diagnosis.2 In fact, the rapid improvement in his cognitive function might argue against COVID-19 encephalitis. Second, our patient’s usual medication included lisinopril, an angiotensin-converting enzyme 2 inhibitor, for treatment of hypertension in the context of diabetes mellitus, type II. Possibly, the mechanism proposed by Annweiler et al pertaining to the nitric oxide track could explain the rapid improvement in our patient’s cognition following just a brief period of supportive management.

It is important to emphasize that delirium is a heterogeneous entity caused by multiple causative factors and complex underlying pathogenesis.3,5 In fact, nitric oxide has long been implicated in the pathogenesis of delirium and cognitive impairment.6-8 Whether the nitric oxide track will prove to have a central role in the acute manifestations of COVID-19–related cognitive impairment remains to be seen. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection could activate multiple downstream molecular pathways affecting each individual distinctly.7 We propose that the underlying mechanism of COVID-19 central nervous system manifestation or delirium depends on the interaction between SARS-CoV-2 activated molecular pathways and the individual related factors, including age, COVID-19 severity, individual’s underlying genetic susceptibility, vascular risk factors, premorbid cognitive function, use of certain medication, and comorbidities.

Several other mechanisms have been linked to COVID-19 neurological and cognitive manifestations.8,9 However, the retrospective design of the study by Mao et al10 limits our ability to infer the causal mechanism of cognitive decline in COVID-19 patients.8 We propose possible mechanisms of COVID-19–related cognitive dysfunction (Table 1), which could help researchers in studying the specific pathways associated with each possible mechanism. Finally, the core message of our study is for clinicians to proactively screen for delirium in hospitalized older adults.10 Once delirium is identified, a comprehensive individualized assessment should
Table 1 Possible mechanisms of COVID-19–related cognitive dysfunction

| Mechanism                                                                 | Description                                                                 |
|---------------------------------------------------------------------------|-----------------------------------------------------------------------------|
| Indirect CNS involvement through inflammatory or immune response         | Viral encephalitis due to direct CNS invasion                                |
| COVID-19–related organ failure (lung, heart, kidney, or vasculature)       | Metabolic dysfunction                                                        |
| COVID-19 ICU–related delirium                                             | Large-vessel stroke or lacunar stroke syndrome                               |
| Exacerbation or unmasking of underlying cognitive impairment or neurodegenerative process | Medication-related adverse reaction                                           |
| Other unknown mechanism                                                   |                                                                             |

Abbreviations: CNS, central nervous system; COVID-19, coronavirus disease 2019; ICU, intensive care unit.

be pursued, including COVID-19 testing during this pandemic.10

Walid A. Alkeridy, MBBS, MSc
Department of Medicine, King Saud University, Riyadh, Saudi Arabia
Division of Geriatric, Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada

Ibrahim Almaghlouth, MBBS, MSc
Department of Medicine, King Saud University, Riyadh, Saudi Arabia
College of Medicine Research Center, King Saud University, Riyadh, Saudi Arabia

ACKNOWLEDGMENTS

The authors would like to thank Salwa Almomen, MBBS, MSc, for reviewing the manuscript.

Conflict of Interest: The authors have no conflict of interest to declare.

Author Contributions: Dr Alkeridy wrote the manuscript. Dr Almaghlouth reviewed, edited, and approved the final version.

Sponsor’s Role: This study was not sponsored by any party.

REFERENCES

1. Annweiler CBA, Fauxon E, et al. Neurological, cognitive and behavioral disorders during COVID-19: the nitric oxide track. J Am Geriatr Soc. 2020. https://doi.org/10.1111/jgs.16536. Online ahead of print.

2. Inouye SK, van Dyck CH, Alessi CA, Balkin S, Siegal AP, Horwitz RI. Clarifying confusion: the confusion assessment method: a new method for detection of delirium. Ann Intern Med. 1990;113(12):941-948.

3. Girard TD, Thompson JL, Pandharipande PP, et al. Clinical phenotypes of delirium during critical illness and severity of subsequent long-term cognitive impairment: a prospective cohort study. Lancet Respir Med. 2018;6(3):213-222.

4. Inouye SK, Westendorp RJG, Saczynski JS. Delirium in elderly people. Lancet. 2014;383(9920):911-922.

5. Dong TG, Tulebaev SR, Inouye SK. Delirium in elderly adults: diagnosis, prevention and treatment. Nat Rev Neurol. 2009;5(4):210-220.

6. Hughes CG, Pandharipande P, Ely EW. Delirium: Acute Brain Dysfunction in the Critically Ill. Cham: Springer; 2020.

7. Iogebu JD, Benamraa CW, Ijimone OM. Potential neurological impact of coronaviruses: implications for the novel SARS-CoV-2. Neuroi Sci. 2020;41:1329-1337. https://doi.org/10.1007/s10072-020-04469-4 [Epub ahead of print].

8. Mao L, Jin H, Wang M, et al. Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. JAMA Neurol. 2020; e201127. https://doi.org/10.1001/jamanetwork.neurology.2020.1127.

9. Pleasure SJ, Green AJ, Josephson SA. The spectrum of neurologic disease in the severe acute respiratory syndrome coronavirus 2 pandemic infection: neurologists move to the frontlines. JAMA Neurol. 2020. https://doi.org/10.1001/jama-neurol.2020.1065. Online ahead of print.

10. Alkeridy WA, Almaghlouth I, Alrashed R, et al. A unique presentation of delirium in a patient with otherwise asymptomatic COVID-19. J Am Geriatr Soc. 2020. https://doi.org/10.1111/jgs.16336. Online ahead of print.

Addressing Hearing Loss to Improve Communication During the COVID-19 Pandemic

To the Editor: Change occurs quickly in emergencies. The coronavirus disease 2019 (COVID-19) response has resulted in rapid modifications in healthcare delivery. Home-based medicine and telemedicine are swiftly evolving and being promptly deployed, as is in-room videoconference technology for inpatients. Necessary precautions, including distancing and personal protective equipment (PPE), have become the norm. Importantly, these changes may exacerbate communication barriers faced by persons with hearing loss.

Hearing loss affects half of all adults older than 60 years.1 However, little consideration is given to addressing hearing loss for effective communication. Hearing loss limits communication via poor auditory encoding of speech signals, resulting in reduced clarity of speech. Cognitive processing, especially working memory, may also be impacted as adults with hearing loss attempt to make sense of poor signals. The stressful, busy, and noisy hospital environment exacerbates problems, leading to limited treatment understanding and increased frustration.

Importantly, poor communication may mediate the association between hearing loss and health outcomes. Adults with hearing loss have increased risk of 30-day readmission, experience longer length of stay, and are less satisfied with care.7 Moreover, hearing loss is associated with poor functional recovery following intensive care unit admissions. Sensory deprivation may increase risk to experience delirium as older adults are cut off from communication and their environment.

The current extended use of PPE during the COVID-19 pandemic limits visualization of the mouth, preventing lip-reading, and acts as a general sound barrier. Even when using videoconferencing equipment, lag and poor image quality may cause significant visual barriers. Coupled with noisy hospital environment (e.g., alarms and constant communication among staff), these visual barriers render the natural sensory substitution compensation methods used by adults with hearing loss as futile. Additionally, distancing may limit access to caregivers or interpreters (American Sign Language) to facilitate conversations during visits.

Thoughtful consideration of addressing barriers is needed (Figure 1). In the outpatient and telehealth setting,

This article was published online on 2 July 2020. An error was subsequently identified in the Acknowledgment section. This notice is included in the online and print versions to indicate that both have been corrected on 15 July 2020.

DOI: 10.1111/jgs.16674